Updated Reviewed

Management of Medication Toxicity or Intolerance

Hematologic Effects

View full version of Table 17d.
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
  
  
  
  

 

References

  1. Arrow Trial Team, Kekitiinwa A, Cook A, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391-1403. Available at: https://pubmed.ncbi.nlm.nih.gov/23473847.
  2. Bunupuradah T, Kariminia A, Chan KC, et al. Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy. Int J Infect Dis. 2013;17(10):e806-e810. Available at: https://pubmed.ncbi.nlm.nih.gov/23764352.
  3. Dollfus C, Le Chenadec J, Mandelbrot L, et al. Improved hematologic outcomes in HIV1-exposed infants receiving nevirapine compared with zidovudine for postnatal prophylaxis in a high resource setting. Pediatr Infect Dis J. 2022;41(5):420-423. Available at: https://pubmed.ncbi.nlm.nih.gov/35135997.
  4. Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. 2011;56(5):428-436. Available at: https://pubmed.ncbi.nlm.nih.gov/21266910.
  5. Esan MO, Jonker FA, Hensbroek MB, Calis JC, Phiri KS. Iron deficiency in children with HIV-associated anaemia: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2012;106(10):579-587. Available at: https://pubmed.ncbi.nlm.nih.gov/22846115.
  6. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis. HIV Med. 2019;20(5):291-307. Available at: https://pubmed.ncbi.nlm.nih.gov/30844150.
  7. Greiter BM, Kahlert CR, Eberhard N, Sultan-Beyer L, Berger C, Paioni P. Lymphocyte subsets in HIV-exposed uninfected infants: the impact of neonatal postexposure prophylaxis with zidovudine. Open Forum Infect Dis. 2020;7(4):ofaa108. Available
  8. Illan Ramos M, Soto Sanchez B, Mazariegos Orellana D, et al. Safety and experience with combined antiretroviral prophylaxis in newborn at high-risk of perinatal infection, in a cohort of mother living with HIV-infant pairs. Pediatr Infect Dis J. 2021;40(12):1096-1100. Available at: https://pubmed.ncbi.nlm.nih.gov/34870390.
  9. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS Res Ther. 2015;12:26. Available at: https://pubmed.ncbi.nlm.nih.gov/26279668.
  10. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J. 2010;29(4):376-379. Available at: https://pubmed.ncbi.nlm.nih.gov/19949355.
  11. Lau E, Brophy J, Samson L, et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. J Acquir Immune Defic Syndr. 2017;74(5):493-498. Available at: https://pubmed.ncbi.nlm.nih.gov/28114187.
  12. Melvin AJ, Warshaw M, Compagnucci A, et al. Hepatic, renal, hematologic, and inflammatory markers in HIV-infected children on long-term suppressive antiretroviral therapy. J Pediatric Infect Dis Soc. 2017;6(3):e109-e115. Available at: https://pubmed.ncbi.nlm.nih.gov/28903520.
  13. Mocroft A, Lifson AR, Touloumi G, et al. Haemoglobin and anaemia in the SMART study. Antivir Ther. 2011;16(3):329-337. Available at: https://pubmed.ncbi.nlm.nih.gov/21555815.
  14. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016;16(2):169-179. Available at: https://pubmed.ncbi.nlm.nih.gov/26481928.
  15. Nanthatanti N, Charoenphak S, Sungkanuparph S. Progression of non-anemic macrocytosis to anemia in HIV-positie persons receiving zidovudine-containing regimens in resource-limited setting. Int J STD AIDS. 2022;33(14):1193-1198. Available at: https://pubmed.ncbi.nlm.nih.gov/36254724.
  16. Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. Pediatr Infect Dis J. 2019;38(7):727-730. Available at: https://pubmed.ncbi.nlm.nih.gov/31033907.
  17. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366(25):2368-2379. Available at: https://pubmed.ncbi.nlm.nih.gov/22716975.
  18. Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012;12:170. Available at: https://pubmed.ncbi.nlm.nih.gov/23114115.
  19. Renner LA, Dicko F, Koueta F, et al. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS. J Int AIDS Soc. 2013;16(1):18024. Available at: https://pubmed.ncbi.nlm.nih.gov/24047928.
  20. Shet A, Bhavani PK, Kumarasamy N, et al. Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. BMC Pediatr. 2015;15:164. Available at: https://pubmed.ncbi.nlm.nih.gov/26482352.
  21. Smith C, Forster JE, Levin MJ, et al. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015;10(5):e0127062. Available at: https://pubmed.ncbi.nlm.nih.gov/26000984.
  22. Smith C, Weinberg A, Forster JE, et al. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir. Infect Dis Obstet Gynecol. 2016;2016:9848041. Available at: https://pubmed.ncbi.nlm.nih.gov/27127401.
  23. Szpak R, Lombardi NF, Dias FA, Borba HHL, Pontarolo R, Wiens A. Safety of antiretroviral therapy in the treatment of HIV/AIDS in children: systematic review and meta-analysis. AIDS Rev.2021;23(4):196-203. Available at: https://pubmed.ncbi.nlm.nih.gov/34082441.
  24. The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. Eur J Clin Pharmacol. 2017;73(4):463-468. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350228.
  25. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198(11):1599-1608. Available at: https://pubmed.ncbi.nlm.nih.gov/19000014.

 

Management of Medication Toxicity or Intolerance

Hematologic Effects

View full version of Table 17d.
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects
  
  
  
  

 

Download Guidelines

Related Content